Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

Politics

HHS slashes over $350M in grant funding for gender ideology, DEI research projects

by admin March 22, 2025
March 22, 2025
HHS slashes over $350M in grant funding for gender ideology, DEI research projects

The Department of Health and Human Services (HHS) has canceled hundreds of National Institutes of Health (NIH) research grants—worth over $350 million—funding projects related to diversity, equity and inclusion (DEI) and gender ideology, according to a department official.

The cuts included slashing projects studying ‘multilevel and multidimensional structural racism,’ ‘gender-affirming hormone therapy in mice’ and ‘microaggressions,’ among others. 

In total, there were more than 500 research grants related to DEI and progressive gender ideology that the administration terminated.

‘HHS is taking action to terminate more than $350 million in research funding that is not aligned with NIH and HHS priorities,’ HHS spokesperson Andrew Nixon said in a statement. ‘The terminated research grants are simply wasteful in studying things that do not pertain to American’s health to any significant degree, including DEI and gender ideology. As we begin to Make America Healthy Again, it’s important to prioritize research that directly affects the health of Americans.’ 

One of the grants cut included nearly $1 million to scientists at the University of Maryland-Baltimore for a research project titled, ‘Assessing intersectional multilevel and multidimensional structural racism for English- and Spanish-speaking populations in the US.’ The project included work to create an ‘intersectional, multilevel, and multidimensional Structural Racism Measure’ in order to ‘eliminate health disparities and discrimination’ for racial minorities.

‘There is an urgent public health need to collect valid and reliable data on structural racism before effective interventions to reduce structural racism can be designed,’ the project’s description stated. 

Multiple projects studying transgender medical treatments in mice were also among those cut. One of those grants provided close to $1 million to Emory University researchers to study how transgender hormone treatments impact the skeletal maturation of mice, titled, ‘Microbiome mediated effects of gender affirming hormone therapy in mice.’ Another project worth roughly $50,000 worked to understand ‘how chromosomal makeup and cross-sex hormone administration’ impacts wound healing in mice.

A separate research project that did not use mice got nearly $1 million ‘to study possible genomic associations with gender identity.’ 

Grants focused on recruiting scientists based on their race or ethnicity were also slashed by the Trump administration. A grant worth more than $5 million to researchers at Vanderbilt University Medical Center to help ‘achieve more racial and ethnic diversity among our scientific research faculty,’ included a commitment to hire at least 18 tenure-track faculty ‘from minoritized racial and ethnic groups.’

Soon after President Donald Trump was inaugurated, he directed federal agencies, including HHS, to temporarily freeze the issuance of new federal grants. The action was to ensure each agency’s funding was in compliance with Trump’s new policies and requirements, including those around getting rid of DEI and progressive gender ideology in the public sector.

A judge subsequently issued an order temporarily blocking the administration’s funding freeze, and shortly thereafter, the Trump administration rescinded its memo directing the funding halt. A short time after that, the NIH resumed important meetings and travel associated with the agency’s grant-review process.  

In addition to reviewing NIH’s grant funding to ensure it aligns with the president’s policies, Trump also implemented a 15% cap on facilities and administrative costs included in research grant awards.

The administration’s actions targeting NIH research have generated widespread backlash. Earlier this month, Trump’s pick to be the next NIH director, Dr. Jay Bhattacharya, was peppered with questions from Democrats during his confirmation hearing over whether he would step in to prevent the president from slashing what they deemed critically important research projects. 

Bhattacharya would not explicitly say he disagreed with the cuts, or that, if confirmed, he would step in to stop them. Rather, he said he would ‘follow the law,’ while also investigating the impact of the cuts and ensuring every NIH researcher doing work that advances the health outcomes of Americans has the resources necessary to do their work. 

Bhattacharya also laid out what he called a new, decentralized vision for future research at NIH that he said will be aimed at embracing dissenting ideas and transparency, while focusing on research topics that have the best chance at directly benefiting the health outcomes of Americans. Bhattacharya said that he wants to rid the agency’s research portfolio of other ‘frivolous’ efforts that he says do little to directly benefit health outcomes.

This post appeared first on FOX NEWS

previous post
Trump rips ‘loser’ Tim Walz for hurting Dems in 2024 election
next post
Operations return to normal at London’s Heathrow Airport after power outage that caused global travel chaos

Related Posts

Judge temporarily blocks Trump order ending collective bargaining...

April 26, 2025

Leader Thune backs Senate GOP bid to speed...

February 6, 2025

Senate Majority Leader Thune says this is the...

February 14, 2025

Tesla robots visit Capitol Hill amid anti-DOGE protests,...

March 27, 2025

Top political handicapper reveals prediction for ‘volatile’ 2026...

February 7, 2025

UN draft report on children in conflict zones...

March 9, 2025

Trump eyes lifting sanctions, potential sale of prized...

March 22, 2025

Trump says he wasn’t ‘trolling’ about acquiring Greenland,...

April 26, 2025

New report reveals how Trump admin will eliminate...

March 29, 2025

Kristi Noem beats Senate confirmation hurdle, advancing to...

January 25, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 2

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 3

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 4

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 5

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 6

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • 7

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 wallstreetwizardry.com | All Rights Reserved